“NIH’s Revolutionary Universal Flu Vaccine Clinical Trial Begins: H1ssF-3928 mRNA-LNP”

2023-05-17 08:22:17

ⓒDaily Post = Image courtesy/Unsplash

ㅣDaily Post=Reporter Kim Jeong-eunㅣA clinical trial on an influenza (influenza) virus mRNA vaccine developed by a research team at the National Institute of Allergy and Infectious Diseases (NIAID) under the National Institutes of Health (NIH) has begun.

Seasonal flu is an annual epidemic not only in Korea but also in the United States. According to the Centers for Disease Control and Prevention (CDC), between 2010 and 2020, between 12,000 and 52,000 people die from the flu every year in the United States alone.

There are many different types of seasonal flu viruses, and the prevalent types are different each time. Therefore, each year before the flu epidemic, it predicts which type will be prevalent and manufactures and distributes a suitable vaccine. However, if the dominant virus changes to an unexpected form, vaccine effectiveness may be compromised.

‘H1ssF-3928 mRNA-LNP’, which is being developed by the NIAID research team, is an mRNA vaccine for the flu virus.

ⓒDaily Post = image courtesy/NIH

There is a protein called hemagglutinin (HA) in the outer membrane of the flu virus. Hemagglutinin changes according to the evolution of flu viruses, but there is little major variation, so hemagglutinins of various flu viruses are very similar. H1ssF-3928 mRNA-LNP is a system that induces immunity against hemagglutinin.

Therefore, the NIH explained that H1ssF-3928 mRNA-LNP is a ‘universal influenza virus vaccine’ that does not require prediction of existing strains and can provide long-term immunity and higher efficacy than existing influenza vaccines.

Up to 50 healthy subjects between the ages of 18 and 49 are recruited for clinical trial registration. Subjects are divided into 3 groups and vaccinated with 10 micrograms, 25 micrograms and 50 micrograms each.

ⓒDaily Post = Image courtesy/Flickr

The study also included a group receiving the current quadrivalent flu vaccine. In order to evaluate the safety of the vaccine, regular checkups will be conducted for up to one year after vaccination.

Hugh Auchincloss, senior deputy director of NIAID, said, “The universal flu virus vaccine is a major public health achievement. In addition, some flu can lead to a pandemic, so a vaccine that prevents all flu may function as an important defense system to prevent it.”

Copyright © Global News Media Channel Daily Post Unauthorized reproduction and redistribution prohibited

#mRNAbased #universal #flu #vaccine #out. #clinical #trial #begins

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.